Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Pushpinder S. Bawa"'
Autor:
Adam J. Hume, Judith Olejnik, Mitchell R. White, Jessie Huang, Jacquelyn Turcinovic, Baylee Heiden, Pushpinder S. Bawa, Christopher J. Williams, Nickolas G. Gorham, Yuriy O. Alekseyev, John H. Connor, Darrell N. Kotton, Elke Mühlberger
Publikováno v:
Pathogens, Vol 13, Iss 1, p 62 (2024)
Single-cell RNA sequencing (scRNA-seq) technologies are instrumental to improving our understanding of virus–host interactions in cell culture infection studies and complex biological systems because they allow separating the transcriptional signat
Externí odkaz:
https://doaj.org/article/73c0987378d64d07b63bcbae717fefc9
Autor:
Rahul, Mannan, Xiaoming, Wang, Pushpinder S, Bawa, Yuping, Zhang, Stephanie L, Skala, Anya K, Chinnaiyan, Aniket, Dagar, Lisha, Wang, Sylvia B, Zelenka-Wang, Lisa M, McMurry, Nikita, Daniel, Xuhong, Cao, Ankur R, Sangoi, Sounak, Gupta, Ulka N, Vaishampayan, Khaled S, Hafez, Todd M, Morgan, Daniel E, Spratt, Maria S, Tretiakova, Pedram, Argani, Arul M, Chinnaiyan, Saravana M, Dhanasekaran, Rohit, Mehra
Publikováno v:
International journal of surgical pathology.
Autor:
Jennifer Hon, Carson Kenum, Pushpinder S. Bawa, Vijaya L. Dommeti, Anastasia A. Sahu, Miriam Gandham, Chi-Chiang Li, Zainab I. Taher, Sylvia Zelenka-Wang, Jean C. Tien, Sunita Shankar, Seema Chugh, Arul M. Chinnaiyan
Publikováno v:
Cancer Research. 82:2538-2538
KRAS mutations have been observed in nearly 95% of pancreatic ductal adenocarcinoma (PDAC), however targeting KRAS remains a major therapeutic challenge. Previous studies from our group have discovered a novel interaction between KRAS and Argonaute 2
Autor:
Adam B, Weiner, Yang, Liu, Matthew, McFarlane, Pushpinder S, Bawa, Eric V, Li, Xin, Zhao, Ziwen, Li, Tanya, Hammoud, Munna, Hazime, R Jeffrey, Karnes, Elai, Davicioni, Zachery R, Reichert, Arul M, Chinnaiyan, Tamara L, Lotan, Daniel E, Spratt, Edward M, Schaeffer
Publikováno v:
Prostate cancer and prostatic diseases. 25(4)
Tumors with mutations associated with homologous recombination deficiency (HRD) are uncommon in prostate cancer (PCa) and variably responsive to PARP inhibition. To better identify tumors with HRD, we developed a transcriptomic signature for HRD in P